/STSA

STSA Stock - Satsuma Pharmaceuticals, Inc.

Q: What is the analyst price target for STSA?

Analyst price target information is not currently available for STSA.

Q: What is STSA's market cap?

Market capitalization information is not currently available for STSA.

Healthcare|Biotechnology|NASDAQ

$1.10+0.00%

+$0.00 (+0.00%) • Jun 7

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $1.21

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for STSA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.10

52W High$8.08

52W Low$0.59

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-70,947,000	$-51,166,000	$-48,328,000	$-28,881,000	$-7,515,000
Net Income	$-69,163,000	$-51,264,000	$-47,674,000	$-28,515,000	$-7,346,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-2.16	$-1.76	$-2.74	$-4.86	$-1.86

Company Overview

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

2 Bullish0 Neutral/Bearish

Price Targets

$16

Average Target

↑ 1309.1% Upside

Now

$15

Low

$16

Average

$16

High

Based on 2 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
October 10th 2022	SVB Leerink	Upgrade	Outperform	$15
August 31st 2022	Ladenburg Thalmann	Initiation	Buy	$16

Earnings History & Surprises

STSA

Beat Rate

27%

Last 15 quarters

Avg Surprise

-15.0%

EPS vs Estimate

Beats / Misses

4/9

2 met exactly

Latest EPS

$-0.31

Q2 2023

EPS Surprise History

Q3 21

0.0%

$-0.38vs$-0.38

Q4 21

+12.5%

$-0.42vs$-0.48

Q1 22

-4.3%

$-0.49vs$-0.47

Q2 22

-2.1%

$-0.49vs$-0.48

Q3 22

-8.3%

$-0.52vs$-0.48

Q4 22

+15.8%

$-0.48vs$-0.57

Q1 23

-84.2%

$-0.70vs$-0.38

Q2 23

-19.2%

$-0.31vs$-0.26

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2024	May 9, 2024	—	—	—	—
Q1 2024	Mar 26, 2024	—	—	—	—
Q4 2023	Nov 1, 2023	—	—	—	—
Q3 2023	Aug 8, 2023	$0.25	—	—	—
Q2 2023	May 11, 2023	$-0.26	$-0.31	-19.2%	✗ MISS
Q1 2023	Mar 28, 2023	$-0.38	$-0.70	-84.2%	✗ MISS
Q4 2022	Nov 3, 2022	$-0.57	$-0.48	+15.8%	✓ BEAT
Q3 2022	Aug 9, 2022	$-0.48	$-0.52	-8.3%	✗ MISS
Q2 2022	May 10, 2022	$-0.48	$-0.49	-2.1%	✗ MISS
Q1 2022	Mar 15, 2022	$-0.47	$-0.49	-4.3%	✗ MISS
Q4 2021	Nov 9, 2021	$-0.48	$-0.42	+12.5%	✓ BEAT
Q3 2021	Aug 10, 2021	$-0.38	$-0.38	0.0%	= MET
Q2 2021	May 11, 2021	$-0.41	$-0.48	-17.1%	✗ MISS
Q1 2021	Mar 25, 2021	$-0.57	$-0.72	-26.3%	✗ MISS
Q4 2020	Nov 10, 2020	$-0.67	$-0.69	-3.0%	✗ MISS
Q3 2020	Aug 12, 2020	$-0.73	$-0.65	+11.0%	✓ BEAT
Q2 2020	May 12, 2020	$-0.68	$-0.68	0.0%	= MET
Q1 2020	Mar 10, 2020	$-0.82	$-0.62	+24.4%	✓ BEAT
Q4 2019	Nov 12, 2019	$-1.01	$-2.26	-123.8%	✗ MISS
Q3 2019	Sep 13, 2019	—	$-0.39	—	—

Frequently Asked Questions about STSA

What is STSA's current stock price?

Satsuma Pharmaceuticals, Inc. (STSA) is currently trading at $1.10 per share. The stock has moved +0.00% today.

What is the analyst price target for STSA?

No analyst price targets are currently available for this stock.

What sector is Satsuma Pharmaceuticals, Inc. in?

Satsuma Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is STSA's market cap?

Satsuma Pharmaceuticals, Inc. has a market capitalization of $0.04 billion, making it a small-cap company.

Does STSA pay dividends?

No, Satsuma Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.